Table 2.
mPDX collections for MSKT. The table reports injection site, engraftment rate, latency of selected collections of MSKT mPDX, and their applications.
| Tumor-Related Features | PDX-Related Features | Applications | Refs. | |||
|---|---|---|---|---|---|---|
| Sarcoma Histotype | Inoculated Mass | Injection Site | Tumor Take (%) | Latency of 1° Passage | ||
| OS and EWS | nd | flank, s.c. | 25/49 (51%) | 16–280 days | modeling | [64] |
| LPS, LMS, MFS, SS, UPS, CHS and other $ | 25–75 mm3 | bilaterally s.c. | 32/188 (17%) | ns | drug testing; Xenosarc platform | [65,66] |
| CHS | 2 mm3 | s.c. | ns | ns | omic analysis | [67] |
| OS | 2–3 mm3 | flank, s.c. | 15/37 (40.5%) | 19–225 days | modeling; clinicopathological correlations | [52] |
| OS and EWS | 4 mm3 | transscapular brown fat, s.c. | OS:22/61 (36%) EW:7/29 (24%) | 1 week–1 year | modeling; target dependencies; drug testing | [53] |
| LPS | 4 × 4 mm | bilaterally s.c. | 7/10 (70%) | 2–9 months | drug testing | [68,69] |
| OS, EWS, RMS | 2 × 2 × 1 mm | s.c. | EW: 17/41 (41.55%); OS: 5/12 (41.7%); RMS: 8/15 (53.3%) | ns | modeling; clinicopathological correlations; drug testing | [70] |
| OS, RMS | 2 × 2 mm3 | flank, s.c. | OS: 51.4% RMS: 53.8% |
300 days | target dependencies | [71] |
| OS | 3 mm3 | flank, s.c. | 9/21 (42.9%) | 3–9 weeks | modeling | [72] |
| LPS | diameter of 3–5 mm | lower back | 25/56 (44.64%) | ns | drug testing | [73] |
| OS | 2 mm in diameter | flank, s.c. | 20/57 (35.1%) | ns | modeling; clinicopathological correlations | [74] |
| LMS | ns | s.c. | 17/49 (35%) | ns | target dependencis | [75] |
| OS, EWS, RMS, SS, other * | 2–5 mm3 | interscapular fat pad, or i.m. | 76/131 (58%) | 12–285 days | modeling; target dependencies; drug testing; MAPPYACTS | [76] |
| Sarcoma (NCI PDXNet consortium) |
ns | s.c. | ns | ns | modeling; clinicopathological correlations; target dependencies | [77] |
| RMS | 25–30 mm3 | flank, s.c. | 50% (6/12) | 195 days (median) | modeling | [78] |
| OS, LMS, LPS | 1–2 mm3 | flank, s.c. | ns | ns | modeling; EuroBoNeT | [79,80] |
| BS | 3 × 3 × 3 mm | flank, s.c. | 16 | 19–125 days | modeling | [63] |
| STS | 5-mm fragments | orthotopic, i.m. or s.c. | 32/107 (29.9%) | 9–184 days | modeling; clinicopathological correlations | [81] |
| OS, EWS, RMS, other § | single-cell suspension | orthotopic | OS 15/31 (48%); RMS 13/20 (65%); EWS 2/7 (29%); other 5/6 (83%) | 1–11 months | modeling; drug screening on primary colture; drug testing | [82] |
| OS, EWS, LPS, UPS, SS other | 2 mm3 | s.c. | 7/12 (58%) | ns | target dependencies and drug identification | [83] |
Notes: ns: not specified; * also includes solid tumors, CNS, lymphoma, and leukemia; $ atypical lipomatous tumor, undifferentiated sarcoma not otherwise specified, solitary fibrous tumor, undifferentiated spindle cell sarcoma, extra-skeletal myxoid chondrosarcoma plus ultra-rarer histotypes, BCOR/CIC; § desmoid small round cell tumor; i.m.: intramuscular; s.c.: subcutaneous.